London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.

Hikma Pharmaceuticals is expanding its market ... and efficiently propel revenue expansion. Competitive Strategy: This report crafts a strong competitive strategy tailored to the hybrid medicine ...

This might drive the stock higher in the near term. Hikma Pharmaceuticals ( LON:HIK ) First Half 2024 Results Key Financial Results Revenue: US$1.57b (up 10.0% from 1H... Shares of Hikma ...

Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a ...

After holding firm till around mid afternoon on Wednesday, European stocks pared gains and closed weak as investors assessed the ...

Global Alcoholic Hepatitis Treatment MarketAccording to a recent analysis by Future Market Insights (FMI), the global ...

Fintel reports that on October 30, 2024, EF Hutton initiated coverage of Carisma Therapeutics (NasdaqGM:CARM) with a Buy ...